logo-loader
Midatech Pharma PLC

Midatech Pharma hails positive results from first in man study

Researchers were assessing the safety of MTX102, which is being designed as a vaccine for type-1 diabetes

1563519208_sterile-room.jpg
The trial now enters what's called the follow-up phase

Midatech Pharma PLC (LON: MTPH.L, NASDAQ:MTP) has announced positive results from a phase I clinical trial of a drug being developed to treat type-1 diabetes.

Researchers were assessing the safety of MTX102, which is being designed as a vaccine. Five patients received the drug and other than some reactions around the injection site “no serious adverse events were reported”.

“The study now enters a follow up stage, at the end of which we will review the data and programme, together with the EU consortium partners,” said Colin Dayan, the lead investigator.

The early-stage assessment was part of an EU project involving a number companies and academic bodies.

Gold nanoparticles 

They are evaluating a vaccine approach for the treatment of type-1 diabetes using Midatech’s gold nanoparticle technology.

The company’s MidaCore technology uses ultra-small gold nanoparticle drug conjugates. And, at just two nanometres, they are among the smallest particles in biomedical use.

They are composed of a core of gold atoms decorated with a permutation of an already-available drug treatment and targeting molecules.

The small size and arrangement around the gold core in theory allows the technology to target immune sites and tumours.

Midatech chief executive Craig Cook said the data generated to date from the first-in-human study helps validate the technology as a “potentially innovative treatment platform for medical applications".

---The shares rose 7% to 5.4p---

Quick facts: Midatech Pharma PLC

Price: £0.06

Market: AIM
Market Cap: £23.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Midatech Pharma PLC named herein, including the promotion by the Company of Midatech Pharma PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: accesso Technology announces deal with The New York...

Top stories from the Proactive Investors UK newsroom: accesso Technology Group PLC (LON:ACSO) has signed a three-year partnership with The New York Botanical Garden (NYBG) to supply its Passport, Siriusware and Ingresso products. Based near The Bronx, the NYBG attracts over 1mln visitors...

on 13/6/19

2 min read